Institutional investors purchased a net $107.2 thousand shares of RNN during the quarter ended March 2018 and now own 5.45% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 161.7 Thousand shares of Rexahn Pharmaceuticals In...
NORTHERN TRUST INVESTMENTS, INC. Bought 29.4 Thousand shares of Rexahn Pharmaceuticals In...